Cargando…

Prostate-Specific Antigen Bounce Following Stereotactic Body Radiation Therapy for Prostate Cancer

Introduction: Prostate-specific antigen (PSA) bounce after brachytherapy has been well-documented. This phenomenon has also been identified in patients undergoing stereotactic body radiation therapy (SBRT). While the parameters that predict PSA bounce have been extensively studied in prostate brachy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vu, Charles C., Haas, Jonathan A., Katz, Aaron E., Witten, Matthew R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904182/ https://www.ncbi.nlm.nih.gov/pubmed/24478988 http://dx.doi.org/10.3389/fonc.2014.00008

Ejemplares similares

Salvage Prostate Stereotactic Body Radiation Therapy After Definitive Cryoablation
por: Lischalk, Jonathan W., et al.
Publicado: (2021)

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
por: Kataria, Shaan, et al.
Publicado: (2017)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Shah, Sarthak, et al.
Publicado: (2021)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Janowski, Einsley-Marie, et al.
Publicado: (2015)

Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer
por: Blacksburg, Seth R., et al.
Publicado: (2020)

Safety of stereotactic body radiation therapy for localized prostate cancer without treatment planning MRI
por: Amarell, Katherine, et al.
Publicado: (2022)

Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease
por: Lischalk, Jonathan W., et al.
Publicado: (2021)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
por: Carrasquilla, Michael, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Small Academic Hospital Experience
por: Factor, Oren B., et al.
Publicado: (2014)

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
por: Ahmed, Kamran A., et al.
Publicado: (2013)

Stereotactic body radiotherapy for organ-confined prostate cancer
por: Katz, Alan J, et al.
Publicado: (2010)

Prostate specific antigen bounce after intensity-modulated radiation therapy in an Asian population
por: Tan, Yu Guang, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect?
por: Katz, Alan J., et al.
Publicado: (2011)

Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Sholklapper, Tamir N., et al.
Publicado: (2022)

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
por: Pepin, Abigail, et al.
Publicado: (2020)

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer
por: Aghdam, Nima, et al.
Publicado: (2020)

Clinical features of prostate-specific antigen bounce after (125)I brachytherapy for prostate cancer
por: Kubo, Katsumaro, et al.
Publicado: (2018)

Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Pepin, Abigail, et al.
Publicado: (2021)

Clinical Characteristics and Management of Late Urinary Symptom Flare Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Woo, Jennifer A., et al.
Publicado: (2014)

Editorial: Stereotactic body radiotherapy for prostate cancer
por: Kishan, Amar U., et al.
Publicado: (2022)

Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
por: Pepin, Abigail, et al.
Publicado: (2021)

Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis
por: Bernstein, Michael B., et al.
Publicado: (2013)

The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups
por: Ricco, Anthony, et al.
Publicado: (2016)

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
por: Bhattasali, Onita, et al.
Publicado: (2013)

Low Incidence of Fatigue after Hypofractionated Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Dash, Chiranjeev, et al.
Publicado: (2012)

Focal Prostate Stereotactic Body Radiation Therapy With Correlative Pathological and Radiographic-Based Treatment Planning
por: Fredman, Elisha, et al.
Publicado: (2021)

The Association of Radiation Dose With Overall Survival for Patients Treated With Prostate Stereotactic Body Radiation Therapy
por: Waters, Michael R, et al.
Publicado: (2023)

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer
por: Gallagher, Lindsey, et al.
Publicado: (2023)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
por: Aghdam, Nima, et al.
Publicado: (2020)

Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer
por: Chen, Lily, et al.
Publicado: (2022)

Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy
por: Hackett, Cian, et al.
Publicado: (2014)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience
por: Mercado, Catherine, et al.
Publicado: (2016)

Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel
por: Kundu, Palak, et al.
Publicado: (2022)

Prostate-specific membrane antigen-based imaging for stereotactic irradiation of low-volume progressive prostate cancer: a single-center experience
por: Varga, Linda, et al.
Publicado: (2023)

Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy
por: Lei, Siyuan, et al.
Publicado: (2011)

Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer
por: Rana, Zaker, et al.
Publicado: (2014)

Intrafraction Prostate Motion Management During Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy
por: Panizza, Denis, et al.
Publicado: (2022)

A Retrospective Review of CyberKnife Stereotactic Body Radiotherapy for Adrenal Tumors (Primary and Metastatic): Winthrop University Hospital Experience
por: Desai, Amishi, et al.
Publicado: (2015)

Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol
por: Liu, Wei, et al.
Publicado: (2022)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lioj0scgl358fa4mur9kbflbfc